Literature DB >> 19687687

Minimally invasive magnetic resonance imaging-guided stereotactic radiofrequency thermocoagulation for epileptogenic hypothalamic hamartomas.

Shigeki Kameyama1, Hiroatsu Murakami, Hiroshi Masuda, Ichiro Sugiyama.   

Abstract

OBJECTIVE: To validate the safety and efficacy of magnetic resonance imaging (MRI)-guided stereotactic radiofrequency thermocoagulation (SRT) for epileptogenic hypothalamic hamartoma (HH), we evaluated surgical outcomes and revised the MRI classification.
METHODS: We retrospectively reviewed 25 consecutive patients with HH (age range, 2-36 years; mean age, 14.8 years) with gelastic seizures. Other seizure types were exhibited in 22 patients (88.0%), precocious puberty in 8 (32.0%), behavioral disorder in 10 (40.0%), and mental retardation in 14 (56.0%). We classified HH into 3 subtypes according to coronal MRI: intrahypothalamic, parahypothalamic, and mixed hypothalamic type. Maximum diameter ranged from 8 to 30 mm (mean, 15.3 mm). All patients underwent SRT (74 degrees C, 60 seconds) for HH.
RESULTS: HH subtype and size were correlated with precocious puberty, mental retardation, and behavioral disorder. Thirty-one SRT procedures were performed, requiring 1 to 8 tracks (mean, 3.8 tracks) and involving 1 to 18 lesions (mean, 7.2 lesions). There were no adaptive limitations, regardless of size or subtype. Mixed-type HHs needed more tracks and more lesions. No permanent complications persisted after SRT, and gelastic seizures disappeared in all but 2 patients. Complete seizure freedom was achieved in 19 patients (76.0%). These patients had not only disappearance of all seizure types and behavioral disorder but also intellectual improvement.
CONCLUSION: The present SRT procedure has favorable efficacy and invasiveness and has no adaptive limitations. SRT should therefore be considered before adulthood. The new HH classification is useful to understand clinical symptoms and to determine surgical strategies.

Entities:  

Mesh:

Year:  2009        PMID: 19687687     DOI: 10.1227/01.NEU.0000348292.39252.B5

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

1.  Freiburg neuropathology case conference: a hypothalamic lesion.

Authors:  Christian Taschner; Sandra Baumgartner; Simone Sackmann; Michael Trippel; Markus Treier; Marco Prinz
Journal:  Klin Neuroradiol       Date:  2009-12

2.  Case report. Gelastic seizures in a patient with right gyrus cinguli astrocytoma.

Authors:  L Nicolae; G Iacob; Mihaela Poparda; B O Popescu
Journal:  J Med Life       Date:  2010 Oct-Dec

3.  Firing behavior and network activity of single neurons in human epileptic hypothalamic hamartoma.

Authors:  Peter N Steinmetz; Scott D Wait; Gregory P Lekovic; Harold L Rekate; John F Kerrigan
Journal:  Front Neurol       Date:  2013-12-27       Impact factor: 4.003

4.  Efficacy and safety of a new robot-assisted stereotactic system for radiofrequency thermocoagulation in patients with temporal lobe epilepsy.

Authors:  Zhaohui Wu; Quanjun Zhao; Zengmin Tian; Jianning Zhang; Xia Xiao; Hong Lin; Hong Wang; Fuli Wang
Journal:  Exp Ther Med       Date:  2014-03-12       Impact factor: 2.447

Review 5.  Stereotactic Laser Ablation for Medically Intractable Epilepsy: The Next Generation of Minimally Invasive Epilepsy Surgery.

Authors:  Michael J LaRiviere; Robert E Gross
Journal:  Front Surg       Date:  2016-12-05

6.  An 11-month-old girl with central precocious puberty caused by hypothalamic hamartoma.

Authors:  Da Young Yoon; Jae Hyun Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-12-31

Review 7.  Anesthetic considerations for stereotactic electroencephalography implantation.

Authors:  Chakrabarti Rajkalyan; Anurag Tewari; Shilpa Rao; Rafi Avitsian
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2019 Oct-Dec

8.  Repeat stereotactic radiofrequency thermocoagulation in patients with hypothalamic hamartoma and seizure recurrence.

Authors:  Hiroshi Shirozu; Hiroshi Masuda; Shigeki Kameyama
Journal:  Epilepsia Open       Date:  2020-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.